RARE DISEASE
Alkaptonuria
Alkaptonuria
Alkaptonuria
Synonyms: Hereditary ochronosis, Homogentisic acid oxidase deficiency
Synonyms: Hereditary ochronosis, Homogentisic acid oxidase deficiency
Synonyms: Hereditary ochronosis, Homogentisic acid oxidase deficiency
Drug discovery
4
drugs
With orphan designations
Overview
Alkaptonuria (AKU) is a rare autosomal recessive disorder caused by HGD gene mutations, resulting in deficient homogentisate 1,2-dioxygenase. This leads to systemic accumulation of homogentisic acid (HGA), causing ochronosis (blue-black connective tissue pigmentation) and early-onset osteoarthritis. Complications include cardiac valve calcification, renal/prostatic stones, and osteoporosis [1][2][7]. Diagnosis involves urinary HGA quantification, genetic testing, and imaging for arthropathy. First-line therapy with nitisinone reduces HGA production, supplemented by symptomatic management (analgesics, joint replacement) [3][6][8].
Burden
Severe quality-of-life impact: Chronic pain, mobility loss, and frequent surgeries (50% require joint replacement by age 55) [4][8].
Increased risks: Cardiovascular disease (22% aortic stenosis), renal stones, and Parkinson’s disease (20× higher prevalence) [9][16][18].
Economic burden: High costs from repeated surgeries and lifelong multidisciplinary care [4][20].
Categories: rare genetic diseases, rare inborn errors of metabolism, rare ophthalmic disorders, rare skin diseases
Research Papers
272 drug discovery papers about Alkaptonuria, with 3 first-in-class and 3 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
272 drug discovery papers about Alkaptonuria, with 3 first-in-class and 3 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-06-30 | SMILES-based degree molecular descriptors and machine learning for QSPR modeling of anti-alkaptonuria drugs.
Quantitative Structure-Property Relationship (QSPR) modelling provides an efficient computational framework for predicting physicochemical properties of drug molecules when experimental data are limited. In this study, we investigate the predictive capability of degree-based topological indices (TIs) derived from SMILES (Simplified Molecular Input Line Entry System) representations for modelling physicochemical properties of anti-alkaptonuria drugs. Nine representative compounds, including Nitisinone, Ascorbic Acid, Ibuprofen, Naproxen, Paracetamol, Tramadol, Methotrexate, Sulfasalazine, and Glucosamine, were analysed using several molecular descriptors such as molecular weight, logP, hydrogen bond donors and acceptors, rotatable bonds, and polar surface area. A total of 58 regression models were developed using Linear Regression (LR) and two machine learning algorithms, Random Forest (RF) and Extreme Gradient Boosting (XGBoost, abbreviated XGB). Model performance was evaluated using Mean Absolute Error (MAE), Mean Squared Error (MSE), Root Mean Squared Error (RMSE), and the coefficient of determination R 2 . The results demonstrate that machine learning models significantly outperform classical regression, with XGB achieving the most accurate and stable predictions for the investigated physicochemical properties. This study introduces a machine learning-driven QSPR framework that integrates SMILES-derived degree-based topological indices with ensemble learning techniques for predicting physicochemical properties of anti-alkaptonuria drugs. The proposed approach demonstrates improved predictive performance on small datasets and highlights the effectiveness of combining graph-theoretic molecular descriptors with advanced machine learning methods.
2026-06-12 | Architecture and dynamics of a supramolecular oxygen transport system in human homogentisate 1,2-Dioxygenase.
Alkaptonuria (AKU) is an ultra-rare inherited metabolic disorder caused by impaired activity of homogentisate 1,2-dioxygenase (HGD), a Fe(II)-dependent enzyme that catalyzes the oxidative cleavage of homogentisic acid in the tyrosine degradation pathway. Although high-resolution structures of human HGD have been solved, a fundamental mechanistic question has remained unresolved: how molecular oxygen reaches the deeply buried catalytic iron required for catalysis. Here, we identify a previously unreported AKU-associated HGD variant, c.925G>A (p.G309R), and use it as a mechanistic perturbation reference to dissect the structural determinants of oxygen access. By integrating replicated classical and steered molecular dynamics simulations with transient pocket detection, tunnel mapping, O2 spatial-occupancy analysis, residue-level tunnel composition, and PCA/tICA-based dynamic validation, we identify a structurally accessible and dynamically supported O2-translocation architecture connecting the central pore of the hexameric enzyme to the non-heme Fe(II) active sites. This pathway is not intrinsic to a single subunit but emerges from a cooperative arrangement of residues contributed by three protomers, generating six symmetry-related O2-access routes per hexamer. The G309R substitution perturbs the architecture and continuity of this tunnel system, providing a mechanistic explanation for enzyme dysfunction without evidence of active-site structural perturbation or global destabilization. Together, our findings support oxygen-tunnel integrity as a previously unrecognized mechanistic requirement for human HGD activity and introduce disruption of oxygen trafficking as an additional pathogenic mode in AKU, with implications for structure-guided variant interpretation and precision-medicine strategies.
2026-06-03 | Deciphering and Improving Human Homogentisate 1,2-Dioxygenase Function Through Knowledge Gaining Directed Evolution: Implications for Alkaptonuria
Abstract Human homogentisate 1,2-dioxygenase (HGD) catalyses the oxidative cleavage of homogentisic acid (HGA) to maleylacetoacetate (MAA), a key step in tyrosine degradation. Loss of HGD activity causes alkaptonuria (AKU), a rare inherited metabolic disorder characterized by toxic HGA accumulation. Current therapy with nitisinone lowers HGA levels but does not restore HGD function, motivating further investigation of HGD structure-function relationships. In this study, we applied the Knowledge Gaining Directed Evolution (KnowVolution) strategy to investigate how amino acid substitutions influence catalytic activity and structural integrity of human HGD. Catalytic activity was evaluated in Escherichia coli using an assay quantifying MAA formation over time. Across four KnowVolution phases, multiple substitutions were identified that modulated catalytic activity while preserving enzyme function. Notably, none of the influential substitutions were located within the catalytic pocket; instead, they occurred predominantly at surface-exposed or structural positions. Structural mapping, interface analysis, and computational stability predictions indicated that some substitutions contribute to hexamer stabilization, whereas others likely alter activity through indirect, non-catalytic mechanisms involving pocket remodelling. Combined substitutions showed non-additive effects that were either cooperative or antagonistic, demonstrating that their impact could not be predicted from individual contributions. Tunnel and pocket analyses showed that N31S, S54D and D86H produced a more compact hexamer, whereas a Q354P+P359E double mutant reduced catalytic pocket solvent accessibility and volume, supporting the observed activity differences. Overall, these findings demonstrate that HGD activity can be modulated by substitutions outside the catalytic pocket, providing new insight into HGD function and genotype-phenotype relationships underlying AKU.
2026-06-02 | Liver-directed AAV gene therapy metabolically corrects AKU in Hgd deficient mice
Abstract Background Alkaptonuria (AKU) is a rare autosomal recessive metabolic disorder caused by deficiency of homogentisate 1,2-dioxygenase (HGD), resulting in systemic accumulation of homogentisic acid (HGA), ochronosis, and progressive multisystem disease. Although nitisinone (NTBC) lowers HGA levels, it does not correct the underlying genetic defect and induces hypertyrosinemia, highlighting the need for curative treatment approaches. We evaluated liver-directed adeno-associated virus (AAV)-mediated HGD gene therapy as a potential treatment for AKU. Methods Hgd-deficient ( Hgd -/- ) mice received liver-directed AAV2/8 vectors expressing codon-optimized human HGD under a liver-specific promoter. Reporter vectors were first used to assess hepatic biodistribution and transduction efficiency. Therapeutic efficacy was subsequently evaluated following AAV2/8-HGD administration (1 x 10 12 vg/mouse). HGD expression was assessed by DNAscope, Western blotting, and RT-qPCR. Metabolic correction was determined using targeted LC-MS/MS and untargeted LC-HRMS metabolomics and compared with NTBC-treated Hgd -/- mice. Results Reporter studies demonstrated liver-predominant transduction, with dose-dependent hepatocyte transduction reaching 89-93% at the highest dose. AAV2/8-HGD treatment produced robust hepatic HGD expression, with codon-optimized human HGD transcript levels approximately 33-fold higher than endogenous murine Hgd expression. Twelve weeks after treatment, plasma and urinary HGA levels were significantly reduced, with plasma HGA restored to near wild-type concentrations. Untargeted metabolomics further demonstrated marked reductions in HGA-derived phase I and II metabolites and revealed significant modulation of tricarboxylic acid cycle metabolism, consistent with partial restoration of metabolic homeostasis. Compared with NTBC-treated mice, AAV2/8-HGD achieved comparable plasma HGA reduction without elevation of upstream tyrosine pathway metabolites. Conclusions Liver-directed AAV2/8-HGD gene therapy achieved substantial biochemical correction in Hgd -/- mice and restored metabolic flux without inducing hypertyrosinemia. These findings provide proof-of-concept supporting AAV-mediated HGD replacement as a promising long-term therapeutic strategy for AKU.
2026-03-01 | 1466: AGGRESSIVE MULTIMODAL MANAGEMENT OF ALKAPTONURIA-INDUCED HEMOLYSIS AND METHEMOGLOBINEMIA
Introduction: Alkaptonuria (AKU) is a rare disorder of the tyrosine metabolic pathway that results in significant accumulation of homogentisic acid (HGA). A fatal complication of AKU is the development of hemolysis and methemoglobinemia. The pathophysiology is thought to be secondary to HGA buildup alongside its oxidative metabolite benzoquinone acetic acid that causes the oxidization of hemoglobin to methemoglobin. This rare and fatal phenomenon has only been described six other times in literature. Description: The patient is a 66 y/o male with PMHx of HFpEF, COPD, AKU who initially presented with a CHF exacerbation. He developed an AKI during diuresis requiring HD. Seven days into his admission he developed hypoxia. An ABG was drawn that showed dark chocolate-colored blood with PO2 of 346. Methemoglobin level was too high to be calculated. LDH was 1,093, haptoglobin undetectably low, and potassium was 6.5, consistent with hemolysis. The patient was started on CVVH. Peripheral smear showed anisopoikilocytosis with bite and blister cells consistent with oxidative hemolysis. The patient was given methylene blue with improvement in his methemoglobin level to 45.4%. The patient was given N-acetylcysteine and high dose ascorbic acid for antioxidant affects. Both plasma exchange and RBC exchange transfusion were utilized to treat the hemolytic anemia. Methemoglobin levels normalized and the patient’s condition stabilized. The orphan drug Nitisinone was emergently obtained. The patient developed a severe ischemic hepatocellular injury 36 hours after presentation resulting in overwhelming vasoplegic shock. He was compassionately extubated and passed shortly after. Discussion: Previous patients have been treated with a combination of antioxidants, methylene blue, and transfusions. Our patient’s condition was rapidly identified and aggressively treated with methylene blue, CVVH, ascorbic acid, NAC, plasma exchange, and exchange transfusion with significant improvement in his condition. Nitisinone, an inhibitor of an upstream enzyme that reduces the production of HGA, was also obtained and started within 24 hours. This combination of therapies has not been reported in literature. We suspect that the combination of our treatments was successful, and it was the initial ischemic injury that led to his demise.
2026-06-30 | SMILES-based degree molecular descriptors and machine learning for QSPR modeling of anti-alkaptonuria drugs.
Quantitative Structure-Property Relationship (QSPR) modelling provides an efficient computational framework for predicting physicochemical properties of drug molecules when experimental data are limited. In this study, we investigate the predictive capability of degree-based topological indices (TIs) derived from SMILES (Simplified Molecular Input Line Entry System) representations for modelling physicochemical properties of anti-alkaptonuria drugs. Nine representative compounds, including Nitisinone, Ascorbic Acid, Ibuprofen, Naproxen, Paracetamol, Tramadol, Methotrexate, Sulfasalazine, and Glucosamine, were analysed using several molecular descriptors such as molecular weight, logP, hydrogen bond donors and acceptors, rotatable bonds, and polar surface area. A total of 58 regression models were developed using Linear Regression (LR) and two machine learning algorithms, Random Forest (RF) and Extreme Gradient Boosting (XGBoost, abbreviated XGB). Model performance was evaluated using Mean Absolute Error (MAE), Mean Squared Error (MSE), Root Mean Squared Error (RMSE), and the coefficient of determination R 2 . The results demonstrate that machine learning models significantly outperform classical regression, with XGB achieving the most accurate and stable predictions for the investigated physicochemical properties. This study introduces a machine learning-driven QSPR framework that integrates SMILES-derived degree-based topological indices with ensemble learning techniques for predicting physicochemical properties of anti-alkaptonuria drugs. The proposed approach demonstrates improved predictive performance on small datasets and highlights the effectiveness of combining graph-theoretic molecular descriptors with advanced machine learning methods.
2026-06-12 | Architecture and dynamics of a supramolecular oxygen transport system in human homogentisate 1,2-Dioxygenase.
Alkaptonuria (AKU) is an ultra-rare inherited metabolic disorder caused by impaired activity of homogentisate 1,2-dioxygenase (HGD), a Fe(II)-dependent enzyme that catalyzes the oxidative cleavage of homogentisic acid in the tyrosine degradation pathway. Although high-resolution structures of human HGD have been solved, a fundamental mechanistic question has remained unresolved: how molecular oxygen reaches the deeply buried catalytic iron required for catalysis. Here, we identify a previously unreported AKU-associated HGD variant, c.925G>A (p.G309R), and use it as a mechanistic perturbation reference to dissect the structural determinants of oxygen access. By integrating replicated classical and steered molecular dynamics simulations with transient pocket detection, tunnel mapping, O2 spatial-occupancy analysis, residue-level tunnel composition, and PCA/tICA-based dynamic validation, we identify a structurally accessible and dynamically supported O2-translocation architecture connecting the central pore of the hexameric enzyme to the non-heme Fe(II) active sites. This pathway is not intrinsic to a single subunit but emerges from a cooperative arrangement of residues contributed by three protomers, generating six symmetry-related O2-access routes per hexamer. The G309R substitution perturbs the architecture and continuity of this tunnel system, providing a mechanistic explanation for enzyme dysfunction without evidence of active-site structural perturbation or global destabilization. Together, our findings support oxygen-tunnel integrity as a previously unrecognized mechanistic requirement for human HGD activity and introduce disruption of oxygen trafficking as an additional pathogenic mode in AKU, with implications for structure-guided variant interpretation and precision-medicine strategies.
2026-06-03 | Deciphering and Improving Human Homogentisate 1,2-Dioxygenase Function Through Knowledge Gaining Directed Evolution: Implications for Alkaptonuria
Abstract Human homogentisate 1,2-dioxygenase (HGD) catalyses the oxidative cleavage of homogentisic acid (HGA) to maleylacetoacetate (MAA), a key step in tyrosine degradation. Loss of HGD activity causes alkaptonuria (AKU), a rare inherited metabolic disorder characterized by toxic HGA accumulation. Current therapy with nitisinone lowers HGA levels but does not restore HGD function, motivating further investigation of HGD structure-function relationships. In this study, we applied the Knowledge Gaining Directed Evolution (KnowVolution) strategy to investigate how amino acid substitutions influence catalytic activity and structural integrity of human HGD. Catalytic activity was evaluated in Escherichia coli using an assay quantifying MAA formation over time. Across four KnowVolution phases, multiple substitutions were identified that modulated catalytic activity while preserving enzyme function. Notably, none of the influential substitutions were located within the catalytic pocket; instead, they occurred predominantly at surface-exposed or structural positions. Structural mapping, interface analysis, and computational stability predictions indicated that some substitutions contribute to hexamer stabilization, whereas others likely alter activity through indirect, non-catalytic mechanisms involving pocket remodelling. Combined substitutions showed non-additive effects that were either cooperative or antagonistic, demonstrating that their impact could not be predicted from individual contributions. Tunnel and pocket analyses showed that N31S, S54D and D86H produced a more compact hexamer, whereas a Q354P+P359E double mutant reduced catalytic pocket solvent accessibility and volume, supporting the observed activity differences. Overall, these findings demonstrate that HGD activity can be modulated by substitutions outside the catalytic pocket, providing new insight into HGD function and genotype-phenotype relationships underlying AKU.
2026-06-02 | Liver-directed AAV gene therapy metabolically corrects AKU in Hgd deficient mice
Abstract Background Alkaptonuria (AKU) is a rare autosomal recessive metabolic disorder caused by deficiency of homogentisate 1,2-dioxygenase (HGD), resulting in systemic accumulation of homogentisic acid (HGA), ochronosis, and progressive multisystem disease. Although nitisinone (NTBC) lowers HGA levels, it does not correct the underlying genetic defect and induces hypertyrosinemia, highlighting the need for curative treatment approaches. We evaluated liver-directed adeno-associated virus (AAV)-mediated HGD gene therapy as a potential treatment for AKU. Methods Hgd-deficient ( Hgd -/- ) mice received liver-directed AAV2/8 vectors expressing codon-optimized human HGD under a liver-specific promoter. Reporter vectors were first used to assess hepatic biodistribution and transduction efficiency. Therapeutic efficacy was subsequently evaluated following AAV2/8-HGD administration (1 x 10 12 vg/mouse). HGD expression was assessed by DNAscope, Western blotting, and RT-qPCR. Metabolic correction was determined using targeted LC-MS/MS and untargeted LC-HRMS metabolomics and compared with NTBC-treated Hgd -/- mice. Results Reporter studies demonstrated liver-predominant transduction, with dose-dependent hepatocyte transduction reaching 89-93% at the highest dose. AAV2/8-HGD treatment produced robust hepatic HGD expression, with codon-optimized human HGD transcript levels approximately 33-fold higher than endogenous murine Hgd expression. Twelve weeks after treatment, plasma and urinary HGA levels were significantly reduced, with plasma HGA restored to near wild-type concentrations. Untargeted metabolomics further demonstrated marked reductions in HGA-derived phase I and II metabolites and revealed significant modulation of tricarboxylic acid cycle metabolism, consistent with partial restoration of metabolic homeostasis. Compared with NTBC-treated mice, AAV2/8-HGD achieved comparable plasma HGA reduction without elevation of upstream tyrosine pathway metabolites. Conclusions Liver-directed AAV2/8-HGD gene therapy achieved substantial biochemical correction in Hgd -/- mice and restored metabolic flux without inducing hypertyrosinemia. These findings provide proof-of-concept supporting AAV-mediated HGD replacement as a promising long-term therapeutic strategy for AKU.
2026-03-01 | 1466: AGGRESSIVE MULTIMODAL MANAGEMENT OF ALKAPTONURIA-INDUCED HEMOLYSIS AND METHEMOGLOBINEMIA
Introduction: Alkaptonuria (AKU) is a rare disorder of the tyrosine metabolic pathway that results in significant accumulation of homogentisic acid (HGA). A fatal complication of AKU is the development of hemolysis and methemoglobinemia. The pathophysiology is thought to be secondary to HGA buildup alongside its oxidative metabolite benzoquinone acetic acid that causes the oxidization of hemoglobin to methemoglobin. This rare and fatal phenomenon has only been described six other times in literature. Description: The patient is a 66 y/o male with PMHx of HFpEF, COPD, AKU who initially presented with a CHF exacerbation. He developed an AKI during diuresis requiring HD. Seven days into his admission he developed hypoxia. An ABG was drawn that showed dark chocolate-colored blood with PO2 of 346. Methemoglobin level was too high to be calculated. LDH was 1,093, haptoglobin undetectably low, and potassium was 6.5, consistent with hemolysis. The patient was started on CVVH. Peripheral smear showed anisopoikilocytosis with bite and blister cells consistent with oxidative hemolysis. The patient was given methylene blue with improvement in his methemoglobin level to 45.4%. The patient was given N-acetylcysteine and high dose ascorbic acid for antioxidant affects. Both plasma exchange and RBC exchange transfusion were utilized to treat the hemolytic anemia. Methemoglobin levels normalized and the patient’s condition stabilized. The orphan drug Nitisinone was emergently obtained. The patient developed a severe ischemic hepatocellular injury 36 hours after presentation resulting in overwhelming vasoplegic shock. He was compassionately extubated and passed shortly after. Discussion: Previous patients have been treated with a combination of antioxidants, methylene blue, and transfusions. Our patient’s condition was rapidly identified and aggressively treated with methylene blue, CVVH, ascorbic acid, NAC, plasma exchange, and exchange transfusion with significant improvement in his condition. Nitisinone, an inhibitor of an upstream enzyme that reduces the production of HGA, was also obtained and started within 24 hours. This combination of therapies has not been reported in literature. We suspect that the combination of our treatments was successful, and it was the initial ischemic injury that led to his demise.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
4 orphan drug designations for Alkaptonuria, including 1 approved therapy.
4 orphan drug designations for Alkaptonuria, including 1 approved therapy.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
nitisinone [Harliku] | small molecules | FDA | 2023-06-12 | 2025-06-10 | Cycle Pharmaceuticals Ltd. |
Methotrexate | small molecules | EMA | 2016-08-29 | — | aimAKU (Associazione Italiana Malati di Alcaptonuria) |
Nitisinone | small molecules | EMA | 2002-03-13 | — | Swedish Orphan Biovitrum AB (publ) |
nitisinone | small molecules | FDA | 2001-10-19 | — | Swedish Orphan Biovitrum AB (publ) |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.